Overview
SEQUENOM CENTER FOR MOLECULAR MEDICINE
Sequenom develops and manufactures tests for the molecular diagnostics market. Its lab-developed tests are primarily focused on prenatal and ophthalmological diseases and conditions. Tests include MaterniT21 Plus (screen for fetal chromosomal abnormalities), HerediT CF (screen for cystic fibrosis genetic mutations), and SensiGene RHD (screen for fetal Rhesus D factor), as well as RetnaGene AMD (predictive test for age-related macular degeneration).
...
Read More The firm formerly offered technology and tools (principally based on its MassARRAY sequencing system) used by researchers, but sold that business in 2014. Sequenom generates about a quarter of sales outside the US. LabCorp acquired Sequenom for $371 million in mid-2016.
Read Less
Read More The firm formerly offered technology and tools (principally based on its MassARRAY sequencing system) used by researchers, but sold that business in 2014. Sequenom generates about a quarter of sales outside the US. LabCorp acquired Sequenom for $371 million in mid-2016.
Read Less
Dirk Van Den Boom
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biological research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
Contacts
Get in Touch with 7 Principals* and 60 Contacts
-
Dirk Van Den BoomPresident and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.